Sohaib Mir has earned a promotion to principal having joined Cambridge Innovation Capital to provide business expertise in the life science space in 2014.
Cambridge Innovation Capital (CIC), the patient capital fund affiliated with University of Cambridge, has promoted life sciences-focused investment employee Sohaib Mir (pictured) to the position of principal.
Mir became the fourth member of CIC’s investment team in 2014. He was most recently responsible for leading CIC’s involvement in Cambridge cancer drug spinout PolyProx Therapeutics’ $4.4m seed round.
Mir has supported CIC’s involvement in a number of life sciences businesses, through roles including board directorships at drug developer Exvastat and University College London-founded cancer diagnostics company Abcodia, and as an observer at Wellcome Sanger Institute microbiome therapy spinout Microbiotica.
Mir was a merger and acquisition analyst for advisory and asset management firm Perella Weinberg Partners from 2012 until 2014.
He completed a three-month internship at investment manager Polar Capital alongside a life science MBE program at University of Cambridge in 2012.
Michael Anstey, investment director at CIC, said: “Over the last five years Sohaib has proved himself to be an invaluable member of the CIC team, possessing the essential mix of scientific knowledge and practical application to the issues commonly encountered by our growing businesses. Promotion to Principal reflects the contribution that he continues to make to the success of CIC.”
